ANI Pharmaceuticals
ANIP
140 hedge funds and large institutions have $325M invested in ANI Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 49 increasing their positions, 53 reducing their positions, and 39 closing their positions.
174% more call options, than puts
Call options by funds: $3.43M | Put options by funds: $1.25M
8% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 53
1.16% less ownership
Funds ownership: 67% → 65.84% (-1.2%)
18% less funds holding
Funds holding: 170 → 140 (-30)
35% less capital invested
Capital invested by funds: $499M → $325M (-$174M)
67% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$6.68M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$5.29M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.72M |
| 4 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
+$3.68M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFC
Phocas Financial Corp
Alameda,
California
|
-$6.26M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.23M |
| 3 |
BlackRock
New York
|
-$4.83M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$2.7M |
| 5 |
Man Group
London,
United Kingdom
|
-$2.29M |
ANIP Hedge Fund Activity: Q1 2020 in Review
140 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2020, worth a combined $325M — down 35% from $499M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ANIP and 13 opened new positions — a net loss of 26 holders — while 53 trimmed existing stakes and 49 added.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $6.68M. The largest seller was Phocas Financial Corp, exiting entirely with an estimated $6.26M sold.
- 140 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2020, down from 170 in Q4 2019.
- Funds reported $325M of ANI Pharmaceuticals stock for Q1 2020, down 35% quarter-over-quarter.
- 13 funds opened new ANI Pharmaceuticals positions in Q1 2020 and 39 closed out, a net change of -26 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2020 was Eagle Asset Management, an estimated $6.68M added.
- The largest ANI Pharmaceuticals seller in Q1 2020 was Phocas Financial Corp, an estimated $6.26M sold.
Based on aggregated 13F filings for Q1 2020.